What is dulaglutide? Structure, research and status

Dulaglutide is a GLP-1 receptor agonist joined to part of an antibody, developed by Eli Lilly and licensed by FDA as Trulicity.

Complete guide9 min read

Key takeaway

Dulaglutide is made of two identical chains, each a GLP-1 analog linked to a modified IgG4 Fc fragment. Its labeled uses are glycemic control in type 2 diabetes from age 10 and lowering major cardiovascular events in some adults with type 2 diabetes. In REWIND, major cardiovascular events occurred in 12.0% on dulaglutide versus 13.4% on placebo. The label carries a boxed warning about thyroid C-cell tumors in rats.

At a glance

Article typeComplete guide
Regulatory statusFDA-approved“Dulaglutide is FDA-approved as the active ingredient in Trulicity.” (this article)
ClassMetabolic & weight
Body systemsEndocrine & metabolism
Studies cited7 in this article · 7 across 1 article on Dulaglutide
Related productsIncretin analogs

Dulaglutide is a lab-made GLP-1 analog fused to the Fc portion of a modified human antibody. The result is a protein of about 63 kilodaltons with an elimination half-life of about 5 days, versus minutes for native GLP-1. FDA licensed it as Trulicity in 2014.

Quick answer: Dulaglutide is a GLP-1 receptor agonist built as a fusion protein. Dulaglutide is FDA-approved as the active ingredient in Trulicity. FDA licensed it as a biological product rather than approving it as a new drug, the route used for liraglutide and semaglutide. Approval covers the labeled product, not research material sold under the same name.

Vitrapep does not sell dulaglutide; this page is a reference summary of published research and regulatory information.

What is dulaglutide and how is it built?

Dulaglutide is a synthetic analog of glucagon-like peptide-1, a hormone the intestine releases after meals (see what GLP-1 is). Eli Lilly researchers developed it under the code LY2189265 [4].

The Trulicity label describes the molecule. Two identical chains are joined by disulfide bonds. In each chain, a small peptide linker connects a GLP-1 analog to the Fc portion of a modified human IgG4 heavy chain [1].

Lilly changed the GLP-1 region that interacts with DPP-4, the enzyme that inactivates native GLP-1. It also changed an area with a potential T-cell epitope. Fc changes target binding to high-affinity Fc receptors and half-antibody formation [1].

Glaesner and colleagues described the engineering in 2010. In cell assays, the fusion protein kept full GLP-1 receptor activity. Its half-life was 1.5 to 2 days in rats and cynomolgus monkeys [4]. These are animal and cell findings, not human data.

FDA regulations define a protein as an alpha amino acid polymer of defined sequence greater than 40 amino acids (21 CFR 600.3). Lilly submitted its application under section 351(a) of the Public Health Service Act, the pathway for biological products (approval letter). Vitrapep's peptide vs protein page explains the distinction.

Table 1

What is dulaglutide and how is it built

PropertyDulaglutide
ClassGLP-1 receptor agonist; Fc fusion protein [1]
StructureTwo identical disulfide-linked chains, each a GLP-1 analog, a small peptide linker and a modified human IgG4 Fc region [1]
Match to human GLP-1(7-37)90% homology in the GLP-1 analog portion [1]
Molecular weightAbout 63 kilodaltons for the whole molecule [1]
Molecular formulaNo PubChem compound record for the whole protein; PubChem lists the GLP-1 moiety (CID 171042928) as C149H221N37O49, 3314.6 g/mol [3]
ProductionMammalian (Chinese hamster ovary) cell culture [1]
Elimination half-lifeAbout 5 days [1]
BreakdownPresumed degraded into amino acids by general protein catabolism [1]
DeveloperEli Lilly and Company, code LY2189265 [2], [4]
US brand and first approvalTrulicity, September 18, 2014, under BLA 125469 [2]
First EU authorizationTrulicity, November 21, 2014 (EMA)

How does dulaglutide work?

Dulaglutide activates the GLP-1 receptor, a cell-surface receptor coupled to adenylyl cyclase in pancreatic beta cells. Activation raises cyclic AMP inside the cell, which leads to insulin release that depends on blood glucose. Dulaglutide also lowers glucagon secretion and slows gastric emptying [1].

In people with type 2 diabetes, both first-phase and second-phase insulin secretion increased compared with placebo. The gastric emptying delay is largest at the start of treatment and then lessens [1].

Duration is the main difference from the natural hormone. Native GLP-1 lasts minutes because DPP-4 inactivates it and the body excretes it quickly [4]. Dulaglutide pairs an altered DPP-4 site with a much larger fusion structure. Liraglutide instead uses an attached fatty acid that binds albumin (see the liraglutide complete guide).

What is dulaglutide approved for?

Section 1 of the Trulicity label lists two uses. The first is improving glycemic control, with diet and exercise, in adults and children aged 10 and older with type 2 diabetes. The second is reducing major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease or multiple risk factors [1].

The label lists no weight-management indication. Safety and effectiveness have not been established in children younger than 10 [1].

FDA approved the original application on September 18, 2014 [2]. The cardiovascular indication followed on February 21, 2020, based on REWIND (approval letter). The pediatric range followed on November 17, 2022 (approval letter). Vitrapep's list of FDA-approved peptide medicines explains how FDA separates peptides from proteins.

What did the key dulaglutide trials show?

REWIND (NCT01394952) ran at 371 sites in 24 countries, with a median baseline HbA1c of 7.2% [5]. The label notes that 62.8% had risk factors without established cardiovascular disease [1]. All-cause death occurred in 10.8% versus 12.0%, a difference that was not statistically significant [5]. In an exploratory analysis, a composite kidney outcome occurred in 17.1% versus 19.6%, with the clearest effect on new macroalbuminuria [6].

AWARD-6 (NCT01624259) tested dulaglutide against liraglutide in adults already taking metformin. Dulaglutide met the noninferiority margin for HbA1c. Nausea occurred in 20% versus 18% [7].

AWARD-PEDS (NCT02963766) found HbA1c below 7.0% in 51% of the pooled dulaglutide groups versus 14% on placebo. Body mass index did not differ between groups [8].

SURPASS-CVOT (NCT04255433) used dulaglutide as the active comparator for tirzepatide, noting it had been shown to reduce cardiovascular events [9]. Tirzepatide was noninferior, and superiority was not shown (see the tirzepatide complete guide).

Table 2

What did the key dulaglutide trials show

TrialPopulation and sizeDesign and lengthPrimary result
REWIND, 2019 [5]9,901 adults aged 50 or older with type 2 diabetes and cardiovascular disease or risk factorsDouble-blind, placebo-controlled; median follow-up 5.4 yearsMajor cardiovascular events 12.0% vs 13.4%; hazard ratio 0.88 (95% CI, 0.79 to 0.99)
AWARD-6, 2014 [7]599 adults with type 2 diabetes on metforminOpen-label, versus liraglutide; 26 weeksHbA1c fell 1.42 vs 1.36 points; noninferior within a 0.4-point margin
AWARD-PEDS, 2022 [8]154 participants aged 10 to under 18 with type 2 diabetesDouble-blind, placebo-controlled for 26 weeks, then 26-week open-label extensionHbA1c rose 0.6 points on placebo; fell 0.6 and 0.9 points in the two dulaglutide groups
SURPASS-CVOT, 2025 [9]13,299 adults with type 2 diabetes and atherosclerotic cardiovascular diseaseDouble-blind, active comparator, versus tirzepatideMajor cardiovascular events 13.1% on dulaglutide vs 12.2% on tirzepatide; hazard ratio 0.92 (95.3% CI, 0.83 to 1.01)

In SUSTAIN 7 (NCT02648204), an open-label trial funded by Novo Nordisk, 1,201 adults received semaglutide or dulaglutide for 40 weeks. HbA1c and body weight fell more with semaglutide at both paired dose levels [10].

What side effects does the Trulicity label list?

Boxed warning. In male and female rats, dulaglutide caused a dose-related and duration-dependent increase in thyroid C-cell tumors after lifetime exposure. It is unknown whether it causes such tumors in humans, including medullary thyroid carcinoma (MTC). It is contraindicated with a personal or family history of MTC or with MEN 2 [1].

One trial participant developed MTC; their calcitonin was about 8 times the upper limit of normal before treatment. REWIND recorded one case of C-cell hyperplasia with raised calcitonin [1].

Common reactions. The most common reactions, each in at least 5% of patients, are nausea, diarrhea, vomiting, abdominal pain and decreased appetite [1]. The pooled placebo-controlled adult data cover 1,670 adults exposed for a mean of 23.8 weeks.

Table 3

What side effects does the Trulicity label list

Adverse reactionPlacebo, % (N=568)Dulaglutide, % (range across the two dose groups, N=836 and N=834)
Nausea5.312.4 to 21.1
Diarrhea6.78.9 to 12.6
Vomiting2.36.0 to 12.7
Abdominal pain4.96.5 to 9.4
Decreased appetite1.64.9 to 8.6
Dyspepsia2.34.1 to 5.8
Fatigue2.64.2 to 5.6

Source: Trulicity label, Table 1 [1]. Stopping because of gastrointestinal reactions occurred in 0.2% on placebo versus 1.3% and 3.5% in the two dose groups [1]. In REWIND, 47.4% on dulaglutide reported a gastrointestinal adverse event, versus 34.1% on placebo [5].

Warnings and precautions. The label warns of acute pancreatitis, including fatal hemorrhagic or necrotizing cases seen with GLP-1 receptor agonists. Confirmed pancreatitis occurred at 1.4 cases per 1,000 patient-years versus 0.88 with non-incretin comparators [1]. In REWIND, diabetic retinopathy complications occurred in 1.9% versus 1.5%, and serious acute cholecystitis in 0.5% versus 0.3% [1].

Other warnings cover hypoglycemia with insulin or sulfonylureas, acute kidney injury from volume depletion and serious hypersensitivity. Pulmonary aspiration during general anesthesia or deep sedation is also listed [1]. Mean heart rate rose 2 to 4 beats per minute in adults. Anti-drug antibodies developed in 1.6% of adults, with no identified clinically significant effect [1].

What changed for dulaglutide labels in 2026?

On March 12, 2026, FDA approved a Trulicity labeling change prompted by a class-wide safety signal on intestinal obstruction and fecal impaction. The postmarketing list now includes intestinal obstruction and severe constipation, including fecal impaction [12].

On November 9, 2026, FDA said all GLP-1 receptor agonist labels must warn of a potential increased risk of NAION, a rare optic nerve condition. Trulicity is on FDA's list. Across 126 randomized trials, NAION occurred at 6.4 cases per 100,000 person-years with GLP-1 receptor agonists versus 3.8 with comparators [13]. See Vitrapep's summary of FDA's GLP-1 eye-risk warning. The DailyMed label, posted August 10, 2026, did not yet include it on November 18, 2026 [1].

What is the regulatory status of dulaglutide?

Biologics license. Trulicity is licensed under BLA 125469 [2]. At approval, FDA required a risk strategy informing prescribers about thyroid C-cell tumors and pancreatitis. It also required postmarketing studies, including an MTC case registry of at least 15 years [11]. In December 2017, FDA said the risk strategy was no longer required (approval letter).

Compounding. FDA's 2018 guidance says biological products subject to licensure under section 351 are not eligible for the compounding exemptions in sections 503A and 503B [14]. Liraglutide and semaglutide medicines were instead approved as new drug applications (NDA 022341, NDA 209637).

Research-labeled products. FDA approval applies to Trulicity as made under its license. A research-use-only label does not make a product legal or safe for people. See research peptides and human-use risks and why research peptides have no dose.

Other countries and sport. The EMA overview describes EU use in adults and children from 10 years of age with type 2 diabetes (EMA). The WADA 2026 Prohibited List does not name dulaglutide or GLP-1 receptor agonists.

What is still unknown about dulaglutide?

The human relevance of the rat thyroid tumors has not been determined [1]. In children, the effect of anti-drug antibodies is unknown because they were uncommon [1]. The controlled pediatric period lasted 26 weeks [8]. The REWIND kidney findings come from an exploratory analysis [6]. FDA found no NAION mechanism in animal data [13].

Frequently asked questions

Is dulaglutide a peptide?

Its GLP-1 portion is a peptide, but the whole molecule is a fusion protein of about 63 kilodaltons. FDA licensed it as a biological product.

Is dulaglutide the same as Trulicity?

Dulaglutide is the active ingredient. Trulicity is the FDA-licensed product, with its own label and approved uses.

How is dulaglutide different from liraglutide and semaglutide?

All three activate the GLP-1 receptor. Dulaglutide is fused to an antibody Fc fragment, while liraglutide and semaglutide carry fatty acid chains.

Does dulaglutide have a boxed warning?

Yes. The Trulicity label warns about thyroid C-cell tumors in rats. Whether dulaglutide causes them in humans is unknown.

Is dulaglutide approved for weight loss?

No. The Trulicity label lists glycemic control in type 2 diabetes and cardiovascular risk reduction in some adults with type 2 diabetes.

Is research-grade dulaglutide FDA-approved?

No. FDA approval applies to Trulicity made under its biologics license. Material sold for laboratory research is not an approved medicine.

What to know now

  • Dulaglutide is a GLP-1 analog fused to a modified IgG4 Fc fragment, with an elimination half-life of about 5 days.
  • FDA licensed Trulicity as a biological product in 2014 and added a cardiovascular indication in 2020.
  • REWIND showed fewer major cardiovascular events than placebo over a median of 5.4 years.
  • In 2026, FDA added intestinal obstruction to the label and required a class-wide NAION warning.

What we’re watching

  • NAION warning text appearing on the Trulicity label.
  • Further SURPASS-CVOT analyses comparing tirzepatide with dulaglutide on heart and kidney outcomes.
  • Any update to FDA's class-wide GLP-1 receptor agonist labeling.

More for endocrine & metabolism

All 48 compounds for endocrine & metabolism

Sources: U.S. National Library of Medicine 2026; U.S. Food and Drug Administration 2026; National Center for Biotechnology Information 2026; Glaesner 2010, Diabetes/Metabolism Research and Reviews, 26; Gerstein 2019, Lancet, 394; Gerstein 2019, Lancet, 394; Dungan 2014, Lancet, 384; Arslanian 2022, New England Journal of Medicine, 387; Nicholls 2025, New England Journal of Medicine, 393; Pratley 2018, Lancet Diabetes & Endocrinology, 6; U.S. Food and Drug Administration 2014; U.S. Food and Drug Administration 2026; U.S. Food and Drug Administration 2026; U.S. Food and Drug Administration 2018. All 14 citations

Back to the research library

References

  1. U.S. National Library of Medicine. (2026). Trulicity (dulaglutide) injection: prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=463050bd-2b1c-40f5-b3c3-0a04bb433309
  2. U.S. Food and Drug Administration. (2026). Drugs@FDA: Trulicity, BLA 125469. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125469
  3. National Center for Biotechnology Information. (2026). PubChem compound summary for CID 171042928, GLP-1 moiety from dulaglutide. https://pubchem.ncbi.nlm.nih.gov/compound/171042928
  4. Glaesner, W., Vick, A. M., Millican, R., et al. (2010). Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. Diabetes/Metabolism Research and Reviews, 26(4), 287-296. https://pubmed.ncbi.nlm.nih.gov/20503261/
  5. Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., et al. (2019). Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet, 394(10193), 121-130. https://pubmed.ncbi.nlm.nih.gov/31189511/
  6. Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., et al. (2019). Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet, 394(10193), 131-138. https://pubmed.ncbi.nlm.nih.gov/31189509/
  7. Dungan, K. M., Povedano, S. T., Forst, T., et al. (2014). Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet, 384(9951), 1349-1357. https://pubmed.ncbi.nlm.nih.gov/25018121/
  8. Arslanian, S. A., Hannon, T., Zeitler, P., et al. (2022). Once-weekly dulaglutide for the treatment of youths with type 2 diabetes. New England Journal of Medicine, 387(5), 433-443. https://pubmed.ncbi.nlm.nih.gov/35658022/
  9. Nicholls, S. J., Pavo, I., Bhatt, D. L., et al. (2025). Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes. New England Journal of Medicine, 393(24), 2409-2420. https://pubmed.ncbi.nlm.nih.gov/41406444/
  10. Pratley, R. E., Aroda, V. R., Lingvay, I., et al. (2018). Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes & Endocrinology, 6(4), 275-286. https://pubmed.ncbi.nlm.nih.gov/29397376/
  11. U.S. Food and Drug Administration. (2014). Trulicity (dulaglutide) BLA 125469: summary review. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125469Orig1s000SumR.pdf
  12. U.S. Food and Drug Administration. (2026). BLA 125469/S-065 supplement approval letter, Trulicity (dulaglutide). https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/125469Orig1s065ltr.pdf
  13. U.S. Food and Drug Administration. (2026). FDA requires safety labeling changes for glucagon-like peptide-1 receptor agonists (GLP-1 RAs) due to potential increased risk of rare but serious eye condition. https://www.fda.gov/drugs/drug-safety-communications/fda-requires-safety-labeling-changes-glucagon-peptide-1-receptor-agonists-glp-1-ras-due-potential
  14. U.S. Food and Drug Administration. (2018). Mixing, diluting, or repackaging biological products outside the scope of an approved biologics license application: guidance for industry. https://www.fda.gov/media/90986/download